Humanigen and Avid Bioservices Enter into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing
February 03, 2021 07:00 ET
|
Avid Bioservices, Inc
BURLINGAME, Calif. and TUSTIN, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced...
Avid Bioservices Announces Closing of Public Offering of Common Stock
December 14, 2020 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Announces Pricing of Public Offering of Common Stock
December 10, 2020 09:00 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Announces Proposed Public Offering of Common Stock
December 09, 2020 16:45 ET
|
Avid Bioservices, Inc
TUSTIN, Ca., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Announces Appointment of Jeanne Thoma to Board of Directors
December 07, 2020 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2021 and Recent Developments
December 02, 2020 16:05 ET
|
Avid Bioservices, Inc
-- Recorded Second Quarter Revenue of $21.1 Million -- -- Signed $28 Million in Business Orders and Ended the Quarter with a Backlog of $67 Million -- -- Initiated First Phase of Myford Expansion --...
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
December 01, 2020 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2021 After Market Close on December 2, 2020
November 24, 2020 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Announces Move to Virtual-Only Annual Meeting of Stockholders on October 20, 2020
September 15, 2020 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), today announced that it will hold its 2020 Annual Meeting of Stockholders (the “Annual...
Avid Bioservices to Participate in 18th Annual Morgan Stanley Global Healthcare Conference
September 10, 2020 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...